12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Envarsus tacrolimus: Phase IIIb started

Veloxis began the open-label, crossover, U.S. Phase IIIb ASERTAA trial to compare once-daily oral Envarsus vs. twice-daily oral tacrolimus in about 72 stable African-American kidney transplant recipients. This quarter, Veloxis plans to submit an NDA to FDA for Envarsus to...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >